GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Aprogen Biologics 003060.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

1,320

+2.25%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Aprogen Biologics

Its shares trade on KRX under the ticker 003060.KS. It has been listed since 19 October 1984. In the fiscal year to 31 December 2025, it reported revenue of ₩73.23bn and a net loss of ₩170.33bn. At that date it held total assets of ₩586.99bn and shareholders' equity of ₩207.76bn.

Aprogen Biologics, Inc. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Seoul, Seoul. The firm operates its business through two segments. The Medicine Business segment is engaged in the manufacture and sale of central nervous system drugs, autonomic agents, arteriosclerosis agents, metabolic agents, circulatory system drugs, biopharmaceuticals and others. The Segment is also engaged in the manufacture and sale of cosmetics such as skin moisturizers and others. The Gaming Business segment is engaged in the development and operation of role-playing games (RPGs).

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
19 Oct 1984

Leadership

Pay as last reported

  • Jae Seop KimCo-Chief Executive Officer, Director, since 2008
  • Mr. Jeong Chul KimCo-Chief Executive Officer, Director
  • Mr. Jong Su KangManaging Director
  • Mr. An Su KimManaging Director
  • Ms. Yun Gyeong BaeAssistant Managing Director
  • Mr. Seon Ju KangAssistant Managing Director
  • Mr. Min Cheol JungInternal Auditor
  • Mr. Seong Ho KangAssistant Managing Director
  • Mr. Dong Cheol ShinNon-Executive Independent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Aprogen Biologics manufactures central nervous system drugs in Seoul, South Korea.
  • The Medicine Business segment sells biopharmaceuticals and cosmetics in the Korean market.
  • The Gaming Business segment develops role-playing games (RPGs) for global audiences.

Weaknesses

  • The company's Gaming Business segment operates in a highly competitive global gaming market.
  • Aprogen Biologics has limited presence in international markets beyond Korea.
  • The Medicine Business segment focuses on a narrow range of pharmaceutical products.

Opportunities

  • Expanding biopharmaceutical sales in the Asian healthcare market offers growth potential.
  • Increasing demand for cosmetics in South Korea supports the Medicine Business segment.
  • The Gaming Business segment can leverage global RPG trends for new revenue streams.

Threats

  • Regulatory changes in South Korea's pharmaceutical industry may impact operations.
  • Competition from international gaming companies threatens the Gaming Business segment.
  • Economic downturns in South Korea could reduce consumer spending on cosmetics.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.